“Real Opportunity” to Boost Diversity in Biotech

The Biotechnology Innovation Organization has set a goal for its member companies to have 50% gender diversity in the C-suite and 30% gender diversity at the board level by 2025. How to achieve that – and other forms of needed diversity at biotech’s upper ranks – was the subject of an interactive discussion between BIO workplace development, diversity, and inclusion (WDDI) committee chairwoman and Halozyme CEO Helen Torley and Chair of BIO’s Board of Directors and Alnylam